Taysha Gene Therapies "announced that an abstract related to its TSHA-102 program in Rett syndrome was accepted for presentation at the upcoming American Society of Gene and Cell Therapy 26th Annual Meeting, taking place in Los Angeles, CA from May 16-20, 2023. The abstract includes new preclinical data from a Taysha-sponsored study for TSHA-102, a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome, a rare neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TSHA:
- Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting
- Taysha Gene Therapies price target lowered to $2 from $13 at Cantor Fitzgerald
- Taysha Gene Therapies price target lowered to $5 from $6 at Chardan
- Taysha Gene Therapies price target lowered to $3 from $4 at Truist
- Taysha Gene Therapies reports Q4 EPS (99c), consensus (33c)